EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
SECTION 09 OF 12 / Evaluate

Scorecard

Compare suppliers only after the essential gates are met.

15Pages
33Sources cited
17 Nov 2026Last updated
Three supplier document folders arranged for comparison on a pharmacy desk
SUPPLIER EVALUATION

Pass the gates.
Then compare the evidence.

Score three candidate arrangements using the research’s weights and evidence ceilings.

Scoring rules →
20%15%20%10%12%8%10%
1. Fulfilment reliability and capacity · 20%2. Continuity and dependency risk · 15%3. Total cost and patient affordability · 20%4. State and cohort operational readiness · 10%5. Workflow, integration and reporting · 12%6. Patient service and nonclinical exception handling · 8%7. Contract flexibility and financial exposure · 10%8. Implementation and accountable governance · 5%

Weights total: 100 / 100. A clinic may change the weights before opening proposals—for example, increasing integration weight during platform consolidation. Record the rationale, retain a 100-point total and apply the same version to every candidate. Do not change weights after seeing which supplier wins.

Criterion / evidenceWeight
Mandatory gates · Any hold or fail prevents ranking
G1 / Counterparty, facility and destination permissions
Evidence to review

Match legal names, addresses and relevant licence identifiers; verify applicable home-state and destination-state permissions; identify subcontracted dispensing locations.

A trading name substitutes for the actual pharmacy; required permissions cannot be verified; an undisclosed facility performs fulfilment.

Owner: Compliance and counsel

Gate
G2 / Product and supply-route eligibility
Evidence to review

Identify approved or compounded status, exact preparation, intended use and statutory pathway. For proposed compounding, obtain preparation-specific clinical and legal review.

Reliance only on patient-specific prescribing, an added ingredient, FDA registration, or a historic shortage.

Owner: Medical director and counsel

Gate
G3 / Provenance and traceability
Evidence to review

Identify the source and distribution chain; obtain relevant transaction records and an allocation of applicable DSCSA responsibilities; test lot identification and quarantine procedures.

Unexplained intermediaries, mismatched labels or invoices, or inability to identify affected supply.

Owner: Pharmacy/quality lead and compliance

Gate
G4 / Quality, storage and recall readiness
Evidence to review

Review facility-specific inspection and remediation records, applicable quality documentation, product-specific storage controls, excursion handling and recall procedures. For eligible compounded preparations, request formulation-relevant testing and dating support.

Material quality concerns remain unresolved; the supplier will not provide sufficient assurance; storage or recall responsibilities are unassigned.

Owner: Qualified quality reviewer and medical director

Gate
G5 / Medication-use safety and clinical independence
Evidence to review

Approve label examples, concentration/device instructions, pharmacist access, complaint and adverse-event escalation, and product-change controls. Prescribing decisions remain with clinicians.

Instructions cannot be reconciled; commercial staff determine treatment changes; clinical escalation has no accountable owner.

Owner: Medical director and pharmacy lead

Gate
G6 / Privacy and security
Evidence to review

Map data flows and legal roles; assess access controls, subcontractors, incident handling and required agreements.

Unapproved data uses, material security gaps, or missing agreements where required.

Owner: Privacy counsel and security lead

Gate
G7 / Financial-arrangement compliance
Evidence to review

Review fees, rebates, ownership links, marketing support and referral-related remuneration under the applicable federal and state framework.

The commercial model depends on payments counsel cannot approve or undisclosed financial interests.

Owner: Counsel and CFO

Gate
Weighted criteria · Rating is capped by the evidence level
1. Fulfilment reliability and capacity
Rating anchors

Weak: Shipping promises without complete order-level evidence; backlog and cancellations omitted.

Acceptable: Defined service windows, reconciled historical data and written capacity commitments support forecast demand.

Excellent: Matched-cohort performance is independently checked across multiple periods; peak-load and exception tests meet the agreed stretch targets.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
2. Continuity and dependency risk
Rating anchors

Weak: A second supplier name is offered without confirmed eligibility, acceptance or capacity.

Acceptable: Approved fallback routes, current acceptance confirmations and a documented interruption playbook.

Excellent: Tested fallback handles the agreed disruption scenario; shared facilities, distributors, software and other common dependencies are mapped.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
3. Total cost and patient affordability
Rating anchors

Weak: Introductory price only; payer responsibilities, later fills or fees are unclear.

Acceptable: Matched full-period model separates clinic, patient and insurer expenditure and stays within approved limits.

Excellent: Quotes reconcile to invoices or test transactions; adverse scenarios remain within buyer-approved limits, with transparent repricing and replacement treatment.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
4. State and cohort operational readiness
Rating anchors

Weak: Licensed coverage is marketed as operational readiness without product acceptance or workflow testing.

Acceptable: Every mandatory state and patient cohort has a named route, acceptance confirmation and launch owner.

Excellent: State/cohort tests demonstrate onboarding, delivery, payment and support; expansion dependencies have dated completion evidence.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
5. Workflow, integration and reporting
Rating anchors

Weak: Status ends at prescription submission; staff chase orders manually.

Acceptable: Receipt, clarification, payment, dispensing, delivery and cancellation statuses are accessible; exports and exception owners are defined.

Excellent: Buyer-tested reconciliation, duplicate protection, outage recovery and usable exports work across all material routes.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
6. Patient service and nonclinical exception handling
Rating anchors

Weak: Patients are passed between clinic and pharmacy; charges and next steps are unclear.

Acceptable: Named ownership, understandable communications and support targets cover routine failures.

Excellent: Measured service consistently meets stretch targets; language/accessibility needs and difficult scenarios are tested.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
7. Contract flexibility and financial exposure
Rating anchors

Weak: Large prepayments, unclear refunds, automatic lock-in or weak exit assistance.

Acceptable: Approved exposure limits, defined remedies, price-change treatment and transition obligations.

Excellent: Executable terms materially limit stranded commitments; exit, reconciliation and transition procedures are tested and commercially usable.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
8. Implementation and accountable governance
Rating anchors

Weak: Launch depends on informal cooperation and an optimistic start date.

Acceptable: Named owners, dependency plan, training, pilot acceptance and review cadence.

Excellent: A controlled rehearsal and pilot meet acceptance criteria; rollback and evidence-refresh responsibilities are demonstrated.

Effective rating: — / 5Effective rating: — / 5Effective rating: — / 5
Candidate A— / 1000Below 70 / 70–79 / 80–100

Documented or verified evidence: 0%

HOLD — unranked

Resolve every gate before a live pilot or supply commitment.

Candidate B— / 1000Below 70 / 70–79 / 80–100

Documented or verified evidence: 0%

HOLD — unranked

Resolve every gate before a live pilot or supply commitment.

Candidate C— / 1000Below 70 / 70–79 / 80–100

Documented or verified evidence: 0%

HOLD — unranked

Resolve every gate before a live pilot or supply commitment.

A HOLD is not an allegation of wrongdoing. A FAIL applies to the assessed arrangement and may be reconsidered after a documented remedy. Neither receives a commercial ranking while unresolved. Evidence coverage is reported separately; it does not multiply the total.

Answers stay in this session unless you choose to save. No account needed.

Read the research

13 pages shown

Research quality self-assessment
9 / 10buyer fit
9 / 10depth
9 / 10search terms
9 / 10sources

The research’s own assessment; not an external rating.